Monoclonal antibody · Antagonist of killer cell immunoglobulin-like receptor (KIR) · developed by Innate Pharma
IPH 2101 is a human monoclonal antibody that binds the inhibitory killer immunoglobulin-like receptor (KIR) on natural killer (NK) cells. By blocking KIR-mediated inhibition, it is intended to permit NK cell-mediated cytotoxicity against tumor cells. It is studied in multiple myeloma and smoldering multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01222286 | Phase 2 | Smoldering Multiple Myeloma | Completed | IPHA |
| NCT01217203 | Phase 1 | Patients With Multiple Myeloma Experiencing a | Completed | IPHA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
First or Second RelapsePatients With Multiple Myeloma Experiencing aSmoldering Multiple Myeloma
Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.
See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IPHA catalysts and pipeline →